127,916 Shares in Theravance Biopharma, Inc. $TBPH Bought by Renaissance Technologies LLC

Renaissance Technologies LLC purchased a new position in Theravance Biopharma, Inc. (NASDAQ:TBPH) in the first quarter, Holdings Channel.com reports. The institutional investor purchased 127,916 shares of the biopharmaceutical company’s stock, valued at approximately $2,076,000.

Several other hedge funds and other institutional investors have also recently bought and sold shares of TBPH. Quarry LP acquired a new position in shares of Theravance Biopharma during the third quarter valued at about $26,000. Caitong International Asset Management Co. Ltd grew its stake in shares of Theravance Biopharma by 107.4% in the 3rd quarter. Caitong International Asset Management Co. Ltd now owns 2,725 shares of the biopharmaceutical company’s stock valued at $40,000 after buying an additional 1,411 shares during the period. Mirae Asset Global Investments Co. Ltd. increased its position in Theravance Biopharma by 26.5% in the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,462 shares of the biopharmaceutical company’s stock valued at $46,000 after buying an additional 515 shares in the last quarter. Tower Research Capital LLC TRC increased its position in Theravance Biopharma by 18.5% in the 2nd quarter. Tower Research Capital LLC TRC now owns 5,013 shares of the biopharmaceutical company’s stock valued at $55,000 after buying an additional 781 shares in the last quarter. Finally, CIBC Private Wealth Group LLC raised its stake in Theravance Biopharma by 20,269.6% during the 3rd quarter. CIBC Private Wealth Group LLC now owns 4,685 shares of the biopharmaceutical company’s stock worth $68,000 after buying an additional 4,662 shares during the period. 99.10% of the stock is owned by institutional investors.

Wall Street Analyst Weigh In

Several research analysts have issued reports on the company. JonesTrading lowered Theravance Biopharma from a “buy” rating to a “hold” rating in a report on Monday, June 29th. Wall Street Zen lowered Theravance Biopharma from a “buy” rating to a “hold” rating in a research report on Saturday, May 16th. HC Wainwright lowered Theravance Biopharma from a “buy” rating to a “neutral” rating and upped their target price for the stock from $15.00 to $17.00 in a research report on Tuesday, July 7th. BTIG Research cut Theravance Biopharma from a “buy” rating to a “neutral” rating in a report on Monday, June 29th. Finally, Zacks Research downgraded shares of Theravance Biopharma from a “strong-buy” rating to a “hold” rating in a research report on Monday, June 8th. Eight equities research analysts have rated the stock with a Hold rating, According to MarketBeat.com, the company has a consensus rating of “Hold” and a consensus price target of $19.40.

Insider Buying and Selling at Theravance Biopharma

In related news, SVP Rhonda Farnum sold 13,314 shares of the company’s stock in a transaction that occurred on Monday, June 15th. The shares were sold at an average price of $16.39, for a total transaction of $218,216.46. Following the sale, the senior vice president owned 232,457 shares of the company’s stock, valued at approximately $3,809,970.23. This represents a 5.42% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, major shareholder Eli Samaha sold 273,871 shares of the stock in a transaction that occurred on Monday, June 29th. The stock was sold at an average price of $17.23, for a total transaction of $4,718,797.33. Following the completion of the sale, the insider owned 9,237,279 shares in the company, valued at $159,158,317.17. This represents a 2.88% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Over the last three months, insiders have sold 350,011 shares of company stock valued at $6,008,309. 7.65% of the stock is owned by corporate insiders.

Theravance Biopharma Price Performance

TBPH opened at $16.91 on Tuesday. The company has a market capitalization of $871.71 million, a price-to-earnings ratio of 7.69 and a beta of 0.19. The firm’s fifty day moving average price is $16.79 and its two-hundred day moving average price is $16.89. Theravance Biopharma, Inc. has a 1 year low of $11.30 and a 1 year high of $21.03.

Theravance Biopharma (NASDAQ:TBPH) last posted its earnings results on Tuesday, March 31st. The biopharmaceutical company reported ($0.10) earnings per share (EPS) for the quarter. The firm had revenue of $17.70 million during the quarter. Theravance Biopharma had a return on equity of 18.84% and a net margin of 104.34%. As a group, equities analysts anticipate that Theravance Biopharma, Inc. will post 1.56 EPS for the current year.

Theravance Biopharma Profile

Theravance Biopharma is a biopharmaceutical company focused on the discovery, development and commercialization of innovative medicines, primarily in the areas of respiratory disease, inflammatory and immunology, and rare disorders. The company develops small-molecule therapies designed to address unmet medical needs by targeting specific molecular pathways. Its lead marketed product, YUPELRI® (revefenacin) inhalation solution, is the first and only once-daily, long-acting muscarinic antagonist (LAMA) approved by the U.S.